Equifin (AMEX:II)
Historical Stock Chart
From May 2019 to May 2024
Ivivi Technologies, Inc. (AMEX:II), a leader in non-invasive,
electrotherapeutic technologies, today announced that it has received
approval for the listing of its common stock on the NASDAQ Capital
Market and intends to withdraw its common stock from listing on the
American Stock Exchange. Ivivi anticipates that trading of its common
stock on the NASDAQ Capital Market will begin on January 2, 2008 under
the symbol NASDAQ: IVVI. Ivivi also expects that the trading of its
common stock on the American Stock Exchange will cease at the close of
business on December 31, 2007.
“The decision to move to NASDAQ was reached
after careful consideration of capital market alternatives and analysis
of the electronic market model, which should provide added visibility to
our investors,” said Andre’
DiMino, Vice Chairman and Co-CEO of Ivivi.
David Saloff, Co-CEO added, “We believe that
NASDAQ’s electronic multiple market maker
structure will provide our Company with enhanced exposure and liquidity,
while at the same time providing investors with better prices, faster
execution, and lower cost per trade. We are proud to be a part of The
NASDAQ Stock Market.”
NASDAQ® is the largest U.S. electronic stock
market. With approximately 3,200 companies, it lists more companies and,
on average, its systems trade more shares per day than any other U.S.
market. NASDAQ is home to companies that are leaders across all areas of
business including technology, retail, communications, financial
services, transportation, media and biotechnology. NASDAQ is the primary
market for trading NASDAQ-listed stocks. For more information about
NASDAQ, visit the NASDAQ Web site at http://www.nasdaq.com
or the NASDAQ NewsroomSM http://www.nasdaq.com/newsroom.
About Ivivi Technologies, Inc.
Based in Northvale, NJ, Ivivi Technologies, Inc. is a medical technology
company focusing on designing, developing and commercializing its
proprietary electrotherapeutic technology platform. Ivivi’s
research and development activities are focused specifically on pulsed
electromagnetic field, or PEMF, technology, which, by creating a
therapeutic electrical current in injured soft tissue, modulates
biochemical and physiological healing processes to help repair the
injured tissue and reduce related pain and inflammation. The Company’s
Electroceuticals™ have been used in
non-invasive treatments for a wide array of conditions, including
chronic wounds, pain and edema following plastic and reconstructive
surgery and chronic inflammatory disorders.
Forward-Looking Statements
This release contains "forward-looking statements" made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform Act
of 1995 including those related to our cardiac study at the Cleveland
Clinic, strategic partnerships and future sales. Forward-looking
statements reflect management's current knowledge, assumptions, judgment
and expectations regarding future performance or events. Although
management believes that the expectations reflected in such statements
are reasonable, they give no assurance that such expectations will prove
to be correct and you should be aware that actual results could differ
materially from those contained in the forward-looking statements.
Forward-looking statements are subject to a number of risks and
uncertainties, including, but not limited to, the Company’s
limited operating history, history of significant and continued
operating losses and substantial accumulated earnings deficit,
difficulties with its financial accounting controls, the failure of the
market for the Company’s products to continue
to develop, the inability for customers to receive third party
reimbursement, the inability to obtain additional capital, the inability
to protect the Company’s intellectual
property, the loss of any executive officers or key personnel or
consultants, competition, changes in the regulatory landscape or the
imposition of regulations that affect the Company’s
products and other risks detailed from time to time in the Company’s
filings with the Securities and Exchange Commission, including the
Company’s Form 10-KSB for the fiscal year
ended March 31, 2007. The Company assumes no obligation to update the
information contained in this press release.